MY134778A - Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization - Google Patents

Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization

Info

Publication number
MY134778A
MY134778A MYPI96004371A MYPI9604371A MY134778A MY 134778 A MY134778 A MY 134778A MY PI96004371 A MYPI96004371 A MY PI96004371A MY PI9604371 A MYPI9604371 A MY PI9604371A MY 134778 A MY134778 A MY 134778A
Authority
MY
Malaysia
Prior art keywords
dna
hyaluronic acid
gene therapy
treat abnormal
retinal vascularization
Prior art date
Application number
MYPI96004371A
Other languages
English (en)
Inventor
Piroska Elizabeth Dr Rakoczy
Professor Ian Jeffery Constable
Original Assignee
Hyal Pharmaceutical Australia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN6161A external-priority patent/AUPN616195A0/en
Priority claimed from AUPN9047A external-priority patent/AUPN904796A0/en
Application filed by Hyal Pharmaceutical Australia Ltd filed Critical Hyal Pharmaceutical Australia Ltd
Publication of MY134778A publication Critical patent/MY134778A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22027—Cathepsin S (3.4.22.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23005—Cathepsin D (3.4.23.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI96004371A 1995-10-23 1996-10-22 Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization MY134778A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN6161A AUPN616195A0 (en) 1995-10-23 1995-10-23 Method and composition for treatment of ocular diseases
AUPN9047A AUPN904796A0 (en) 1996-04-01 1996-04-01 Method and composition for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MY134778A true MY134778A (en) 2007-12-31

Family

ID=25645043

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI96004371A MY134778A (en) 1995-10-23 1996-10-22 Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization

Country Status (8)

Country Link
EP (1) EP0859636A4 (fr)
JP (1) JP2000507915A (fr)
KR (1) KR19990066967A (fr)
CN (1) CN1209068A (fr)
CA (1) CA2235685A1 (fr)
MY (1) MY134778A (fr)
NZ (1) NZ320006A (fr)
WO (1) WO1997015330A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739601B2 (en) 1991-07-03 2001-10-18 Meditech Research Limited Use of hyaluronan in gene therapy
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
WO1998013024A2 (fr) * 1996-09-27 1998-04-02 Hyal Pharmaceutical Corporation Systeme hyaluronique d'administration de medicaments
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
CN101011584A (zh) * 1999-12-28 2007-08-08 诺瓦提斯公司 获得持续的转基因表达的方法
ES2349137T3 (es) * 2000-06-20 2010-12-28 Dainippon Sumitomo Pharma Co., Ltd. Preparación para transferir oligonucleótidos.
DK1407787T3 (da) 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremme af nukleinsyreoverförsel
WO2003070256A1 (fr) * 2002-02-15 2003-08-28 Research Development Foundation Tranduction adenovirale induite par l'acide hyaluronique
WO2004105784A1 (fr) * 2003-05-29 2004-12-09 The University Of Manchester Agonistes des slrp de classe iii servant a reduire la formation de vaisseaux sanguins
JP5255277B2 (ja) * 2004-10-05 2013-08-07 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 網膜疾患の検診装置
BRPI0609151B8 (pt) 2005-03-24 2021-05-25 Life Sciences Res Partners Vzw molécula de ligação ao antígeno capaz de se ligar a plgf, usos da mesma, linhagem celular de hibridoma, composição farmacêutica e polinucleotídeo
US7867490B2 (en) 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
CN1742623A (zh) * 2005-07-13 2006-03-08 凌沛学 透明质酸磷脂复合物及其制备方法
DK2352761T3 (en) 2008-10-02 2016-10-03 Vib Vzw INHIBITION OF PLGF TO TREAT PHILADELPHIA CHROMOSOMPOSITIVE LEUKEMIS
AU2012321082B2 (en) 2011-12-01 2015-03-12 Oxurion NV Improving trabeculectomy outcome
KR101420751B1 (ko) * 2011-12-12 2014-07-17 서강대학교산학협력단 망막 질환 치료제 후보물질의 스크리닝 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2636339B1 (fr) * 1988-09-09 1992-07-17 Auge Pier Gel aqueux a base d'acide hyaluronique et d'acide desoxyribonucleique utilisable en cosmetique, et procede de preparation
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
WO1992013063A1 (fr) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Procedes permettant de moduler par transcription l'expression de genes de facteurs de croissance et de genes de recepteurs de facteurs de croissance
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
WO1996000286A1 (fr) * 1994-06-27 1996-01-04 Toagosei Co., Ltd. Compose d'acide nucleique antisens

Also Published As

Publication number Publication date
KR19990066967A (ko) 1999-08-16
CA2235685A1 (fr) 1997-05-01
NZ320006A (en) 2001-12-21
EP0859636A1 (fr) 1998-08-26
EP0859636A4 (fr) 2002-05-02
WO1997015330A1 (fr) 1997-05-01
JP2000507915A (ja) 2000-06-27
CN1209068A (zh) 1999-02-24

Similar Documents

Publication Publication Date Title
MY134778A (en) Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
DE69400208D1 (en) Olionukleotidalkylphosphonate und -phosphonothioate
CA2229171A1 (fr) Procede de modulation de l'expression d'un gene provoquant une reponse immunostimulatrice reduite
WO1996023065A3 (fr) Inhibition de la neoformation de vaisseaux sanguins au moyen d'oligonucleotides specifiques de vegf
WO2001048190A8 (fr) Utilisations therapeutiques d'oligonucleotides a lna modifie
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
EP0939621A4 (fr) Inhibition de l'expression de la proteine bcl-2 par des nucleotides olidodesoxy antisens se presentant sous forme de liposomes
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
EP2252688A1 (fr) Oligonucléotides à fonction phosphodiester et leurs utilisations thérapeutiques
WO1999015643A3 (fr) COMPOSITIONS OLIGONUCLEOTIDIQUES ANTISENSE CIBLEES SUR L'ARNm DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET METHODES D'UTILISATION
ZA981609B (en) Method of treating a tumor
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
AU2672099A (en) Compositions and methods for wound healing
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
NO991292L (no) Anvendelse av benzopyranoler for Õ behandle nevrologiske forstyrrelser
DE69625919D1 (de) Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation
WO1997010334A3 (fr) Therapie ribozymiale pour le traitement et/ou la prevention de la restenose
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
DE69938501D1 (de) Verwendung von prohibitin-rns in krebsbehandlung
AU7266496A (en) Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
HK1077306A1 (en) Ocular gene therapy
EP1374909A3 (fr) Evaluation des agents adaptés au traitement de cardiopathies, administration et utilisation de tels agents
DE60224078D1 (de) Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
李敏 CLINICAL OBSERVATION ON POSTHERPETIC NEURALGIA OF HIV CARRIERS TREATED WITH ARRANGED ELECTRO ACUPUNCTURE